ClinicalTrials.gg
Enrolling by invitationNCT05722145GPS-CADUpdated Dec 4, 2025

Global Pretest Probability Study of Coronary Artery Disease

An observational study in Coronary Artery Disease, sponsored by National Heart Centre Singapore. Enrolling by invitation at 1 site in Singapore. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by National Heart Centre Singapore · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100,000
Ages
21 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Coronary Artery Disease by National Heart Centre Singapore — 5 open to participants now, 7 under way, none of them phase 3. Coronary Artery Disease · National Heart Centre Singapore.

Started
2022
with 1 other
Observational
9 of 11
4 open now
Registered
10th of 11
by date

Among the 11 studies in Coronary Artery Disease by National Heart Centre Singapore, this one is one of 2 that started in 2022, is one of 9 observational ones, and was the 10th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 11 studies in Coronary Artery Disease by National Heart Centre Singapore are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 21 Years to 99 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Coronary Artery Disease by National Heart Centre Singapore, or all of them as a file.
02

Study summary

The use of pre-test probability (PTP) and coronary artery calcium (CAC) scores is guideline-recommended in the evaluation of coronary artery disease (CAD) and stable chest pain. The utility of these scores is population dependent. Previous studies have predominantly been limited to Western populations, despite Asia forming 60% of the global population. However, Asian populations have differing coronary artery phenotypes and may therefore have different PTPs with varying implications for risk stratification. Known difference in CAC implications support a global approach. Hence, this study aims to evaluate a contemporary PTP in diverse real-world Asian, Western and other cohorts and to evaluate the incremental value of CAC in predicting CAD and events. Primarily, the study will compare population specific PTPs and CAC for prediction of coronary computed tomography angiography (CTA) CAD. This could be compared with existing guideline-recommended PTPs alone or with consideration of risk factors or CAC. The study will also evaluate the accuracy of the prediction of major adverse cardiovascular events (MACE) using PTP models, risk factors and/or CAC. Lastly, the study will investigate the accuracy of zero CAC and other minimal risk tools to de-risk cardiovascular disease (CVD) in various populations.

The study will investigate multiple international cohorts of patients referred for noninvasive testing using coronary CTA or other non-invasive imaging modalities. Locally-calibrated PTP models in consideration of risk factors or CAC will be separately tailored to each different cohort, and will be evaluated.

Read the detailed description

This study is an aggregated registry comprising of a retrospective medical record review of individuals from multiple sites. The general approach is to create a large, consolidated, global registry of existing cohorts of patients referred for noninvasive testing using computed tomography (CT). Anonymized images and structured data, including demographics, risk factors, outcomes and CT results will be obtained from multiple sites. The types of images to be analyzed and quantified are non-contrast CT (NCCT) scans and coronary CT angiography (CCTA). CAC score will use Agatston's method while CAD will be assessed using registry data of CCTA reads.

The data collected will include risk factors and demographics such as age, sex, ethnicity, hypertension, smoking, diabetes, dyslipidemia and family history of CAD. Outcomes such as death and myocardial infarctions will be included in the dataset if available. All data received will be anonymized and de-identified. Study team members will check through the study data to ensure that all study data is accurately collected and complete.

The data elements of different cohorts may not harmonize or match with each other. There could be missing data elements or different data inputs. As such, omission or imputation may be used to perform analyses. To minimize data heterogeneity in format, sites will be provided with a standard template and data dictionary. This will complete the initial data harmonization and expected data elements. The collected dataset would then be harmonized by the biostatistics team prior to analysis.

The approximate total study size n = 100,000. Assuming an area under the receiver operating curve (AUC) of 0.70 for existing PTP and CAC methods, this proposal is adequately powered to detect an increase of 0.05 in AUC using a two-sided z-test at a significance level of 0.05. Continuous variables will be expressed as mean and standard deviation. Categorical variables will be expressed as absolute numbers and percentages. Distributions will be tested for normality using Shapiro-Wilk statistics. Non-normally distributed variables will be represented as median with 25th to 75th interquartile range. Comparison of normally distributed continuous variables will be performed using Student's t test for paired and unpaired data. Non-normally distributed variables will be compared using Mann-Whitney Rank Sum tests and Kruskal-Wallis tests. Comparison of categorical data will be performed using Chi-square and Fisher's Exact Tests where appropriate.

Differences in outcomes over time will be analyzed by the Kaplan-Meier analysis with log-rank test for each outcome. Using Cox regressions analysis univariate and multivariate regression analyses will be performed. Univariate analysis will include pre-event variables with p values \<0.10. Variables that showed a significant (p\<0.05) correlation with the endpoints, after univariate analysis, will be considered in the multivariate models. Odds ratios and 95% confidence interval will be calculated. Statistical significance was established as p\<0.05. Advanced machine learning techniques (e.g. neural networks) may be applied.

03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
21 Years to 99 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Across hospitals and research centres across multiple countries

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of participants are more than or equals to 21 years old
  • The subjects need to have underwent computed tomography angiography (CTA) or non-contrast computer tomography (NCCT) for assessment of coronary artery disease.

Exclusion criteria

Exclusion Criteria:

  • Age less than 21 years old
  • Subjects who are unable to undergo cardiac CT
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. To evaluate and optimize contemporary risk and PTP tools for use in diverse real-world global cohorts by pooling data from multiple large CTA/CAC studies worldwide

    Time frame: Throughout study, expected to be 5 years

Secondary outcomes

  1. To evaluate and compare existing PTPs and CAC for prediction of CTA-defined CAD using PTP alone, with risk factors (RF) and/or CAC

    Time frame: Throughout study, expected to be 5 years

  2. To compare the accuracy of prediction of major adverse cardiovascular events (MACE) using PTP alone, with RF and/or CAC

    Time frame: Throughout study, expected to be 5 years

  3. Determine population-specific optimizations for risk prediction of CAD and MACE and evaluate these newly-modified PTP

    Time frame: Throughout study, expected to be 5 years

  4. To compare accuracy of zero CAC and minimal risk tools to exclude CAD in various populations (de-risk)

    Time frame: Throughout study, expected to be 5 years

07

Study locations

1 site
08

References and documents

Publications

  • Baskaran L, Selva JJ, Mantri AVI, Douglas PS; GPS-CAD Investigators. Design and Rationale of GPS-CAD: Global Pretest Probability Study of Coronary Artery Disease. JACC Asia. 2025 Dec 30:S2772-3747(25)00695-7. doi: 10.1016/j.jacasi.2025.11.016. Online ahead of print. PubMed 41904715 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Aug 2027, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2023
First posted
Feb 10, 2023
StartActual
Nov 25, 2022
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05722145
Lead sponsor
National Heart Centre Singapore
Responsible party
Sponsor
First posted
Feb 10, 2023
Start date
Nov 25, 2022
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Dec 4, 2025

Study contacts

Lohendran Baskaran
principal investigator · National Heart Centre Singapore
Pamela Douglas
study chair · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion